Age of end-stage kidney disease development in autosomal dominant polycystic kidney disease
Abstract
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent monogenic disease of the kidney, leading to end-stage kidney disease (ESKD) in a large proportion of patients. This work aimed to assess the age of ESKD development in ADPKD patients in consecutive decades. It was assumed that parallelly to improved advancement and accessibility to diagnostics and therapy, the clinical efficiency enhances, what evinces in increased age in which ESKD occurs.
Material and methods: Retrospective analysis of data of ADPKD patients treated in the study centre. No patient was treated with tolvaptan before ESKD since tolvaptan was not available in Poland at that time.
Results: 139 patients were included and divided into 3 groups: group I (ESKD before the year 2006), group II (ESKD between 2006 and 2015) and group III (ESKD in 2016 or later). The mean age of ESKD development was 43.47, 52.65, and 55.23 in groups I, II, and III, respectively. There were statistically significant differences in the age of ESKD between groups I and III (p = 0.0086), but not between groups I and II, nor II and III.
Conclusions: The age of ESKD development in the course of ADPKD was higher in the last decade compared to the turn of the last century. This effect was not associated with tolvaptan, while patients analysed in the present study were not treated with it. That suggests that even without tolvaptan, efforts towards modification of lifestyle, diet, and treatment of concomitant diseases may delay ESKD development in ADPKD.
Keywords: ageautosomal dominat polycystic kidney disesaeend-stage kidney disease
References
- Rangan G, Alexander S, Campbell K, et al. KHA‐CARI guideline recommendations for the diagnosis and management of autosomal dominant polycystic kidney disease. Nephrology. 2016; 21(8): 705–716.
- Chapman AB, Devuyst O, Eckardt KU, et al. Conference Participants. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2015; 88(1): 17–27.
- Cornec-Le Gall E, Audrézet MP, Chen JM, et al. Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol. 2013; 24(6): 1006–1013.
- Müller RU, Messchendorp AL, Birn H, et al. An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International. Nephrol Dial Transplant. 2022; 37(5): 825–839.
- Borowiecka J, Pączek L, Niemczyk M. Tolvaptan in autosomal dominant polycystic kidney disease — a real-life experience. Medical Research Journal. 2024; 9(2): 130–135.
- Gall ECL, Audrézet MP, Rousseau A, et al. The PROPKD Score. Journal of the American Society of Nephrology. 2016; 27(3): 942–951.
- Rozpara K, Serwik-Trandasir A, Niemczyk M. Multimorbidity in autosomal dominant polycystic kidney disease. Gerontol PoL. 2022; 30: 163–168.